Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries.

Journal of immunological methods·2021

Same author

The immunological response to traumatic brain injury.

Journal of neuroimmunology·2019

Same author

The use of psychoactive agents in veterinary medicine.

International journal of pharmaceutical compounding·2013

Same author

First use of alemtuzumab in Balo's concentric sclerosis: a case report.

Multiple sclerosis (Houndmills, Basingstoke, England)·2013

Same author

Retrospective evaluation of the diagnostic accuracy of Parkinsonism in a UK community based movement disorders clinic.

Parkinsonism & related disorders·2012

Same author

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Neurology·2012

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Rationale for cytotoxic monoclonal antibodies in MS.

B S Simpson¹, A J Coles

¹Department of Clinical Neurosciences, Addenbrookes Hospital, Hills Road, Cambridge, CB2 2QQ, UK.

International MS Journal

|August 10, 2007

Summary

This summary is machine-generated.

Monoclonal antibodies (MAbs) show promise in treating multiple sclerosis (MS). Their efficacy may stem from immune system modulation during reconstitution, not just cell depletion.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

Immunology
Neuroscience
Pharmacology

Background:

Monoclonal antibodies (MAbs) are established therapies for inflammatory and neoplastic disorders.
Cytotoxic MAbs have been utilized in experimental allergic encephalomyelitis, a model for multiple sclerosis (MS).
Antibodies targeting lymphocytic antigens have yielded variable results in MS treatment.

Purpose of the Study:

To explore the therapeutic potential of monoclonal antibodies in multiple sclerosis.
To investigate the mechanism of action of monoclonal antibodies in MS treatment.
To evaluate the role of immune reconstitution in MAb efficacy for MS.

Main Methods:

Review of existing literature on MAb applications in MS.
Analysis of data from studies using antibodies like alemtuzumab (anti-CD52).
Postulation of mechanisms based on clinical observations and experimental models.

Main Results:

Monoclonal antibodies are effective in treating various human diseases.
Clinical efficacy of some MAbs in MS might be linked to immune modulation.
Immune system reconstitution following MAb therapy may contribute to therapeutic benefits.

Conclusions:

Monoclonal antibodies offer a specific and scalable therapeutic approach.
The mechanism of action for certain MAbs in MS may involve immunomodulation.
Further research into immune reconstitution is warranted for optimizing MAb therapy in MS.